

Arthritis Research UK

Conditions for the award of a Grant

These Conditions, the Letter of Award (and any special conditions (“Special Conditions”), financial summaries or policy guidelines appended to or referred to in the Letter) from Arthritis Research UK and the Acceptance of Conditions of Award signed by the grant holder (“the Grant Holder”) and by the host institution (“the Host Institution”) set out the entire agreement (“the Grant Contract”) between Arthritis Research UK and the Grant Holder and the Host Institution for the award of the grant (“the Grant”) specified in the Letter of Award.

If there is any conflict between these Conditions and the provisions of the Letter of Award or of any documents referred to in it, such provisions shall prevail.

Where the Letter of Award names co-applicants, the Grant Holder must ensure that all co-applicants comply with the Grant Holder’s obligations under the Grant Contract.

The Host Institution must ensure that the Grant Holder complies with their obligations under the Grant Contract.

The Host Institution warrants that the person who signed the Acceptance of Conditions of Award on its behalf was duly authorised to do so and to bind the Host Institution to the Grant Contract.

1 EMPLOYMENT OF STAFF

- 1.1 Arthritis Research UK does not act as an employer and, therefore, in all cases where support is provided by the Grant for the employment of staff, the Host Institution or its permitted sub-contractor(s) must issue a contract of employment for such staff in accordance with the relevant laws and regulations. (Except as set out in Condition 16.3) Arthritis Research UK will not be responsible for, nor will it indemnify the Host Institution against, any claim for redundancy, compensation, dismissal or discrimination or any other claims for which the Host Institution or any permitted sub-contractor may be liable as an employer, or otherwise.
- 1.2 The Host Institution is responsible for the management, monitoring and control of all the work funded as the result of the Grant and all those persons (including employees, students and visiting fellows) employed or involved in any work funded as a result of the Grant.
- 1.3 The Host Institution must ensure that all permanent and temporary staff and students employed or involved in the work funded by the Grant receive training appropriate to their duties, in accordance with any applicable legal or regulatory requirements, including any necessary to support the requirement for management, monitoring and control as described in Condition 1.2.
- 1.4 The Host Institution must recruit all employees funded by the Grant in compliance with its requirements and recommendations for good practice in recruitment. Arthritis Research UK may require representation on recruitment panels in certain circumstances, in which case, this will be set out in the Special Conditions.

- 1.5 The salary and employment benefits to be provided and the length of contract to be issued will be a matter for agreement between the post holder, the Grant Holder and the Host Institution or its permitted sub-contractor.
- 1.6 Upon appointment of any employee funded by the Grant, the Host Institution must inform Arthritis Research UK of full details of their appointment date, salary level and contract length. No payment of the Grant relating to the salary costs of such employee shall be made until this information is provided. The Host Institution must also notify Arthritis Research UK where an employee identified in the application fails to take up the appointment and when an employee funded by the Grant leaves together with the date of termination.
- 1.7 Arthritis Research UK does not pay the cost of maternity, paternity or adoption leave (or other leave to which an employee is entitled by statute or his employment contract) for people employed on the Grant. As the Host Institution is the employer, it is responsible to discharge all employer statutory and contractual payments for such leave, including any entitlement to remuneration during leave for sickness or injury, and Arthritis Research UK will not supplement the Grant for this purpose.
- The Grant Holder must inform Arthritis Research UK of the dates in advance of any maternity, paternity or adoption leave, and promptly where leave for sickness or injury has lasted more than 10 consecutive working days, of an employee funded by the Grant. Payment of the Grant (to the extent it relates to the salary costs of, or the work undertaken by, the employee on leave) will be suspended for the period of such maternity, paternity or adoption leave and may at Arthritis Research UK's discretion be suspended for the period of leave for sickness or injury lasting more than 10 consecutive working days. If the employee returns to work after the maternity, paternity or adoption leave on a lesser time commitment, Arthritis Research UK and the Host Institution acting in good faith shall determine whether the period of the Grant should be extended to accommodate the new working basis.
- 1.8 Should a person whose salary is supported by the Grant subsequently obtain salary support from some other source, that salary provision in the Grant may not be transferred to any other individual or use without Arthritis Research UK's prior written approval.
- 1.9 The Host Institution must ensure that any permitted sub-contractor complies with Condition 1 in respect of any of its employees, students and visiting fellows funded by the Grant.

2 CLINICAL FELLOWSHIPS

All holders of clinical fellowships who are involved in the work funded by the Grant must be an employee of, or hold an honorary clinical contract with, a National Health Service body.

3 EQUIPMENT FUNDED BY THE GRANT

- 3.1 The Host Institution must ensure that any equipment funded by the Grant has adequate insurance cover. If the equipment is damaged, destroyed or stolen during its useful lifetime the Host Institution must repair or replace it. On payment of the Grant for the purchase of equipment, Arthritis Research UK has no liability to make further payments for the purchase if the equipment is not delivered to the Host Institution or the Grant Holder.
- 3.2 When purchasing equipment funded by the Grant, the Host Institution must adhere to its own standard procurement procedures.
- 3.3 Without prejudice to Condition 3.6, should the Grant Holder move to another institution within the United Kingdom during the period of the Grant or within 3 years of the end of the Grant period, Arthritis Research UK reserves the right to require that the equipment be transferred with them after discussion, as necessary, with the institutions concerned.
- 3.4 If the Grant is made for the purchase of large, multi-user items of equipment specifically to provide departmental infrastructural support and the Grant Holder moves to another

institution, either during or following the end of the Grant period, the equipment will remain in the Host Institution.

- 3.5 If any equipment to be used by the Grant Holder or named co-applicants was provided by a previous Arthritis Research UK grant, either to the current Grant Holder or to any other person, Arthritis Research UK will not provide funds for usage or access charges for the equipment in question. This Condition covers all equipment (including personal computers) purchased with funds provided by Arthritis Research UK.
- 3.6 The Host Institution must maintain the equipment during its useful lifetime so that it is capable of operating for its intended purpose. The equipment must not be disposed of during this period without Arthritis Research UK's prior written approval.

4 TRANSFER TO ANOTHER INSTITUTION

- 4.1 Should the Grant Holder or a named co-applicant move to another institution during the period of the Grant, the Grant may not transfer with them unless agreed by Arthritis Research UK, the Grant Holder and the Host Institution. Arthritis Research UK will not be obliged to provide additional grant monies as a result of such a transfer.
- 4.2 If the Grant Holder moves to another institution but Arthritis Research UK does not consent to the transfer of the Grant to that institution, the Host Institution must ensure that one of its employees, whose work is funded by the Grant, undertakes in writing to Arthritis Research UK to be bound by this Grant Contract as if originally named as the Grant Holder (to the extent obligations remain to be performed by the Grant Holder).

5 CLINICAL TRIALS

- 5.1 Where the Grant is made available for clinical trials, each of the Grant Holder and the Host Institution must comply with the Special Conditions.
- 5.2 The Host Institution shall, when carrying out clinical trials funded by the Grant,
- 5.2.1 comply with all applicable laws and Department of Health ("DH") guidance relevant to the clinical trial including but not limited to UK legislation implementing the EU Clinical Trials Directive (2001/20/EC) and other relevant EU Directives, the Human Tissue Act 2004, the DH "Research Governance Framework for Health and Social Care" and any other relevant statutory requirements and/or government guidance in force from time to time;
- 5.2.2 conduct clinical trials in accordance with the terms of all relevant regulatory permissions and approvals, which may include but not be limited to Clinical Trial Authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA), ethics approval from National Research Ethics Service (NRES), the terms of any National Health Service and Health and Social Care (HSC) clinical trials agreement, the letter of no objection from the MHRA for the investigation of a non CE marked medical device or a CE marked device being used for the new purpose and the permission given by or on behalf of any NHS site R&D management;
- 5.2.3 comply with Data Protection Act 1998 requirements and any relevant clinical trials medical confidentiality principles as may be in force from time to time;
- 5.2.4 adhere to the principles on the review of patient identifiable information and materials in the Caldicott Committee Report on the review of patient identifiable information;
- 5.2.5 not disclose and ensure that no third party discloses the identity of participants to third parties;
- 5.2.6 (where it is intended that trial data is to be published) register the clinical trial on the International Standard Randomised Controlled Trials Number (ISRCTN) Register.

6 FINANCIAL ARRANGEMENTS

- 6.1 No payments of the Grant shall be made until both the Grant Holder and the Host Institution have signed the Acceptance of Conditions of Award relating to the Grant.
- 6.2 The maximum amount of Grant monies which may be claimed is specified in the Letter of Award. Except for Grants for fellowships or any other personal awards, funds within the Grant may be freely moved within all budget headings set out in the financial summaries referred to in the Letter of Award at the Grant Holder's discretion, provided that Arthritis Research UK is informed of any changes.
- 6.3 The Grant must be activated within 12 months of the scheduled start date stated in the Letter of Award. Any change to the start date of the Grant must be notified to Arthritis Research UK in advance.
- 6.4 (Except for grants for the purchase of equipment for which see Condition 6.5 below) payment of the Grant will be made to the Host Institution quarterly in arrears, unless specified in the Special Conditions, or otherwise agreed, subject to receipt by Arthritis Research UK of a duly completed claim setting out the costs properly incurred by the Host Institution during the preceding quarter which are covered by the Grant. The claim must contain sufficient detail to enable Arthritis Research UK to verify the costs incurred against the Grant headings in the financial summaries referred to in the Letter of Award. Arthritis Research UK may request such additional information from the Host Institution or the Grant Holder as is reasonably necessary to carry out such verification.
- 6.5 Payment of the Grant relating to expenditure properly incurred under the Grant for the purchase of equipment will be made to the Host Institution within 21 days of receipt of a claim for payment.
- 6.6 The final claim will only be accepted if it is submitted within 12 months of the end of the Grant period.
- 6.7 Arthritis Research UK will retain 5% (or such higher percentage specified in the Special Conditions) of the Grant at Arthritis Research UK's discretion until the Grant Holder delivers the final report under Condition 15.1 when it shall be paid in full, subject to Condition 7 (Arthritis Research UK's right to withhold payment) and setting off against it any overpayment of the Grant.
- 6.8 The control of expenditure to be funded under the Grant must be governed by the normal standards and procedures of the Host Institution and must be covered by the formal audit arrangements that exist in the Host Institution.
- 6.9 At Arthritis Research UK's request the Host Institution must obtain confirmation from its internal auditors of the following:
- 6.9.1 that the annual accounts of the Host Institution have been audited by the auditors without qualification;
- 6.9.2 that the management letter from the auditors confirmed that proper systems of internal control were in place, and that there were no matters that did or could significantly affect the administration of grants awarded by Arthritis Research UK;
- 6.9.3 that the Grant has been used for the purpose for which it was awarded.
- 6.10 Arthritis Research UK may, both during and after the Grant period, appoint auditors of its own choice to request confirmation from the external or internal auditors of the Host Institution of amounts paid by Arthritis Research UK in respect of the Grant. In addition, Arthritis Research UK may, both during and after the Grant period, at its cost, commission a separate audit of the Grant, the expenditure incurred on the Grant funded work and/or the systems used by the Host Institution to administer Arthritis Research UK grants, including the system of equipment procurement, and, in so doing, it may or may not seek to use the internal audit function of the Host Institution.

- 6.11 Arthritis Research UK may on reasonable notice during normal business hours, both during and after the Grant period, inspect either itself or by its authorised representatives the records of the Host Institution and any permitted sub-contractor relating to the Grant, the work funded by the Grant and the expenditure incurred on such work and any equipment or facilities funded by the Grant and take copies at Arthritis Research UK's expense. The Host Institution shall ensure that Arthritis Research UK has such access to a sub-contractor's records.
- 6.12 The Grant shall be automatically terminated (without any liability of Arthritis Research UK) if it is not activated within 12 months of the scheduled start date set out in the Letter of Award or if the Host Institution has not made any claims for payment within a 12 month period.
- 6.13 Arthritis Research UK may demand reimbursement of any overpayment of the Grant which is not offset under Condition 6.7.

7 WITHHOLDING OF GRANT

If the Grant Holder or the Host Institution has failed to comply with this Grant Contract, Arthritis Research UK may withhold payment of any instalment of the Grant until the non-compliance is remedied to Arthritis Research UK's reasonable satisfaction.

8 REPAYMENT OF GRANT

Arthritis Research UK may by written notice to the Host Institution demand within 21 days repayment of the Grant made to the extent of that part of the Grant (if any) which:

- 8.1 has not been applied for the Grant purposes stated in the Letter of Award; or
- 8.2 has been spent on items of expenditure not allowed by the Grant Contract; or
- 8.3 has been paid by Arthritis Research UK for items of expenditure which have also been funded directly by a third party other than the Host Institution.

9 FUNDING FROM INDUSTRY

- 9.1 Each of the Host Institution and the Grant Holder agree not to accept funding, drugs, human tissue, materials or other support from pharmaceutical, biotechnology and other healthcare commercial companies ("Industry Support") for an activity which is funded by the Grant without Arthritis Research UK's prior written consent (including Arthritis Research UK's consent to the terms thereof and any exploitation by such companies of intellectual property arising from such activity).
- 9.2 Each of the Host Institution and the Grant Holder must notify Arthritis Research UK promptly (giving reasonable details) if they receive, and wish to accept, an offer of Industry Support in regard to work supported in part or in full by the Grant.

10 LIMITATIONS OF ARTHRITIS RESEARCH UK's LIABILITY

- 10.1 (Except for its obligations to pay the Grant in accordance with the Grant Contract and as set out in these Conditions), Arthritis Research UK accepts no responsibility, financially or otherwise, for the expenditure (or liabilities arising out of such expenditure) or liabilities arising out of work funded by the Grant. Arthritis Research UK will not be liable for, and will not indemnify the Host Institution, the Grant Holder, any named co-applicants and anyone else engaged on work supported by the Grant against, claims, costs, expenses and liabilities for which any such person may be liable.
- 10.2 The Host Institution is responsible for all acts and omissions of its employees and students (or those of any permitted sub-contractor) in connection with work funded by the Grant.

10.3 Nothing in this agreement excludes or limits Arthritis Research UK's liability for fraud or for death or personal injury arising from its negligence.

11 INTELLECTUAL PROPERTY AND COMMERCIAL ACTIVITIES

11.1 The Host Institution must:

11.1.1 develop and implement strategies and procedures for the identification, protection, management and exploitation of all intellectual property created or acquired in connection with an activity funded by the Grant (intellectual property includes without limitation all inventions, discoveries, materials, technologies, products, data, databases, software, patents, copyright and know-how) ("the Arthritis Research UK Funded IP");

11.1.2 notify Arthritis Research UK promptly when Arthritis Research UK Funded IP that may be of medical or commercial value is created, and ensure that such Arthritis Research UK Funded IP is protected and not published or otherwise publicly disclosed prior to protection (whilst at the same time ensuring that potential delays in publication are minimised);

11.1.3 permit Arthritis Research UK to have reasonable access to personnel, facilities and information utilised in, or created or acquired pursuant to, an activity funded by the Grant or the exploitation envisaged under this Condition 11;

11.1.4 ensure that all persons in receipt of Arthritis Research UK funding or working on an activity funded by the Grant (including employees, students, visiting fellows and sub-contractors) are employed or retained on terms that vest in the Host Institution all Arthritis Research UK Funded IP;

11.1.5 inform Arthritis Research UK of any proposal to exploit the Arthritis Research UK Funded IP (giving reasonable details);

11.1.6 not enter into any agreement for the exploitation of the Arthritis Research UK Funded IP without Arthritis Research UK's prior written consent, such consent not to be unreasonably withheld.

11.2 No Arthritis Research UK Funded IP may be exploited in any way without Arthritis Research UK's prior written consent, such consent not to be unreasonably withheld. Exploitation includes use for any commercial purpose or any licence, sale, assignment, materials transfer or other transfer of rights. As a condition of granting such consent, Arthritis Research UK will require the Host Institution to agree terms of exploitation including the sharing of the benefits arising from the exploitation in accordance with Condition 12 below.

11.3 If the Host Institution does not protect or exploit any Arthritis Research UK Funded IP to Arthritis Research UK's satisfaction, Arthritis Research UK shall have the right, but not a duty, to protect, manage and exploit such Arthritis Research UK Funded IP. The Host Institution must, and must ensure that its employees, students, agents and sub-contractors, do all acts required to assist Arthritis Research UK in such protection, management and exploitation.

11.4 The Host Institution shall ensure that separate and accurate records are maintained of the commercial exploitation of the Arthritis Research UK Funded IP and access for Arthritis Research UK or its appointed representative to inspect and audit such records and to take copies at Arthritis Research UK's expense.

11.5 In order to support Arthritis Research UK's obligation to ensure that the useful results of research that it funds are applied for the public benefit, the Host Institution must permit Arthritis Research UK free use of any published material and the copyright therein created or acquired in connection with an activity funded by the Grant. Arthritis Research UK undertake to give due acknowledgement of the Host Institution and Grant Holder in any publication.

11.6 Condition 11 shall continue to apply after termination of the Grant Contract.

12 INTELLECTUAL PROPERTY REVENUES AND EQUITY SHARING

Revenue or equity benefits resulting from the exploitation of Arthritis Research UK Funded IP are to be shared as follows:

12.1 Technology transfer fees

The organisation exploiting the Arthritis Research UK Funded IP will be entitled to receive a percentage of Net Income received as follows (“Technology Transfer Fee”):

Cumulative Net Income	Technology Transfer Fee
£0 to £100,000	30%
£100,001 to £500,000	25%
Greater than £500,000	20%

“Direct Costs” are all costs reasonably incurred by such organisation exclusively attributable to the exploitation of the Arthritis Research UK Funded IP, including patent fees and professional costs.

“Net Income” is all income received in respect of the exploitation of the Arthritis Research UK Funded IP less Direct Costs.

12.2 Host Institution and Arthritis Research UK revenue sharing

Net Income received less Technology Transfer Fees shall be distributed between the Host Institution and Arthritis Research UK in the following proportions:

Cumulative Net Income	Host Institution & Inventors	Arthritis Research UK
£0 to £100,000	65%	35%
Greater than £100,000	60%	40%

The Host Institution is responsible for any distribution to the inventor(s) from its share of net income.

12.3 Equity Sharing

Any sharing of equity between the Host Institution or the Grant Holder or Arthritis Research UK or others (which includes shares, loan stock, debenture stock and options and other interests in a company) which arises from exploitation of Arthritis Research UK Funded IP must be agreed with Arthritis Research UK.

12.4 Condition 12 shall continue to apply after termination of the Grant Contract.

13 ASSIGNMENT OF INTELLECTUAL PROPERTY

13.1 A Special Condition may require that all copyright and other intellectual property rights subsisting in any part of the world created as a result of work funded by the Grant shall be assigned to and vest absolutely in Arthritis Research UK. At the request of Arthritis Research UK, the Host Institution must, and must procure that the individuals involved in such work must, execute such deeds and documents and do such other acts and things as may be necessary to achieve the assignment with full title guarantee.

13.2 Conditions 11 and 12 do not apply to intellectual property rights covered by Condition 13.1.

14 GOOD SCIENTIFIC PRACTICE

- 14.1 Arthritis Research UK requires the highest standards of integrity to be adhered to by the researchers whom it funds with the Grant. The Host Institution must have in place its own published standards of good research practice and formal written procedures for the investigation of allegations of scientific misconduct and shall make those available to Arthritis Research UK on request. Such standards must take into account the Association of Medical Research Charities' 'Guidelines on Good Research Practice'.
- 14.2 In the event of any investigation of scientific misconduct, both during or after the Grant period, involving research or researchers funded by the Grant:
- 14.2.1 Arthritis Research UK must be informed within 7 days of the Host Institution initiating any such investigation of scientific misconduct. Arthritis Research UK reserves the right to suspend the Grant in the event of any suspension of staff paid from the Grant while the investigations are ongoing.
- 14.2.2 Arthritis Research UK must be informed immediately of the outcome and reserves the right to take any further action it may feel appropriate, including termination of the Grant with immediate effect.
- 14.2.3 If publications have been produced where academic fraud has been established, the Host Institution must ensure that appropriate errata and/or retractions are promptly published and that Arthritis Research UK is notified promptly of all such actions.
- 14.3 Each of the Host Institution and the Grant Holder must comply, and must ensure that any permitted sub-contractor complies, with all relevant laws, regulations and Government guidance applicable to, and obtain and maintain all licences and approvals required for, the research funded by the Grant in each country in which it is conducted, and also any regulations and policy of the Host Institution relating to the use of animals in research.
- 14.4 The Host Institution must ensure that the useful results of the research are disseminated. The Host Institution must properly evaluate the research before it is published and, if the results are to be published in a reputable scientific or medical journal, may rely on an evaluation of quality by the journal concerned.

15 PROGRESS REPORTS, PUBLICATIONS AND PUBLICITY

- 15.1 The Grant Holder must complete a final report on the outcomes of the Grant, in a format prescribed by Arthritis Research UK, within 6 months of the end of the period of the Grant. Arthritis Research UK reserves the right to request interim reports in writing or by interview as and when required by Arthritis Research UK.
- 15.2 The Grant Holder must co-operate fully with Arthritis Research UK in carrying out assessments of the success or failure of all of its funded work, both during and after the period of the Grant. This may include recommendations to build on individual pieces of work.
- 15.3 The Grant Holder and Host Institution must ensure that documents relating to the Grant are retained for a period of not less than 10 years after the end of the period of the Grant to allow assessment, including that specified in Condition 15.2.
- 15.4 The Grant Holder should note that failure to submit a report or to co-operate with Arthritis Research UK's assessment of their work may cause Arthritis Research UK to withhold payment of the Grant and refuse to consider further grant requests from the Grant Holder and their department.
- 15.5 The Grant Holder and the Host Institution must acknowledge Arthritis Research UK in all publications and presentations arising from work carried out under the Grant and in all correspondence and advertisements relating to the appointment of staff to work in

connection with the Grant. When acknowledging Arthritis Research UK support, the Arthritis Research UK grant reference number must be quoted.

- 15.6 On acceptance for publication of articles in peer reviewed journals, Arthritis Research UK must be informed and a copy of the final manuscript of all peer reviewed research papers supported in whole or in part by the Grant must be deposited in an open access archive such as the PMC database and any other PMC International (PMCI) sites, such as UK PubMed Central (UKPMC), to be made freely available within 6 months of publication. Any exceptions to this must be sanctioned by Arthritis Research UK.
- 15.7 The Grant Holder and the Host Institution must inform the Arthritis Research UK Press Office well in advance of any intended press statement associated with the Grant or wholly or partly with the research funded by the Grant, and ensure that such a press statement is approved by Arthritis Research UK's Press Officer prior to release. The Grant Holder must support a press release announcing the award of the Grant.
- 15.8 Arthritis Research UK recognises that publication of the results of research funded by the Grant may need to be delayed for a reasonable period while seeking protection of intellectual property arising from the research. However, any such periods of delay in publication should be kept to a minimum.

16 TERMINATION OF GRANT

- 16.1 Arthritis Research UK may terminate its obligations to pay the Grant and the Grant Contract:
- 16.1.1 (where there has been no material breach of the Grant Contract by the Host Institution or the Grant Holder) immediately on written notice to the Host Institution and the Grant Holder; or
- 16.1.2 immediately by written notice to the Host Institution and the Grant Holder if the Grant Holder or the Host Institution is in material breach of the Grant Contract and (if capable of remedy) fails to remedy the breach within 30 days of a written request to do so.
- 16.2 On termination, Arthritis Research UK will reimburse the Host Institution for expenditure properly incurred under the terms of the Grant up to the termination date (to the extent not already covered by a previous Grant payment).
- 16.3 If Arthritis Research UK terminates pursuant to Condition 16.1.1 (but not otherwise) and the full amount of the Grant has not been paid at the termination date, it shall reimburse to the Host Institution any redundancy or other liabilities arising out of the termination of employment it incurs directly as a result of the termination of the Grant but only in respect of any staff who had been funded by the Grant. The amount reimbursed shall not exceed the amount of the Grant which would otherwise have been payable in respect of the period after the termination date.
- 16.4 Termination of the Grant shall not affect the continuance of any provision of the Grant Contract expressly or implicitly surviving termination.
- 16.5 As at termination of this Grant Contract the accrued right of the parties to the Grant Contract shall not be affected (subject to Condition 16.2).

17 VARIATION OF CONDITIONS

- 17.1 Arthritis Research UK may at any time propose a variation to any of, or an addition to, these Conditions or any Special Conditions. Such a variation or addition shall not be effective unless approved in writing by the Grant Holder, Host Institution and Arthritis Research UK.
- 17.2 A proposed change to the end date of the Grant must be notified to Arthritis Research UK for approval which shall not be unreasonably withheld.

18 GENERAL

- 18.1 A person who is not a party to this Grant Contract shall have no rights under the Contracts (Rights of Third Parties) Act 1999 (as modified or re-enacted) to enforce any of its terms.
- 18.2 Neither the Host Institution nor the Grant Holder may assign the benefit of this Grant Contract, or sub-contract the performance of its or their obligations, without Arthritis Research UK's prior written consent, such consent not to be unreasonably withheld.
- 18.3 If a notice has to be given under this Grant Contract, it must be sent by first class recorded delivery post or by electronic communication to the recipient at the address notified for that purpose and will be regarded as received within 2 days of posting or 24 hours after the transmission of the electronic communication.
- 18.4 This Grant Contract may be executed in any number of counterparts, each of which when executed and delivered shall constitute an original of this Grant Contract, but all the counterparts shall together constitute the same agreement.

19 GOVERNING LAW

This Grant Contract shall be governed by, and construed in accordance with, the laws of England. The Grant Holder, the Host Institution and Arthritis Research UK irrevocably submit to the exclusive jurisdiction of the Courts of England to settle any dispute or claim which arises out of this Grant Contract.
